Edition:
United Kingdom

People: Chiasma Inc (CHMA.OQ)

CHMA.OQ on NASDAQ Stock Exchange Global Select Market

5.18USD
23 Aug 2019
Change (% chg)

-- (--)
Prev Close
$5.18
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
174,554
52-wk High
$9.23
52-wk Low
$2.12

Fitzpatrick, Mark 

Mr. Mark J. Fitzpatrick serves as President, Principal Financial Officer of the Company. He has been our President and Chief Executive Officer since October 2016, and prior to that was our Chief Financial Officer since June 2015. Prior to joining us, he was Chief Financial Officer at Aegerion Pharmaceuticals, Inc., Dynogen Pharmaceuticals, Inc., WorldStreet Corporation, and Diacrin, Inc., and has more than 25 years of financial management experience in both public and private companies. Mr. Fitzpatrick began his professional career at Arthur Andersen LLP. Mr. Fitzpatrick received his B.S. in Accounting from Boston College in 1984 and earned a Certified Public Accountant certificate in the Commonwealth of Massachusetts in 1987. We believe Mr. Fitzpatrick’s extensive knowledge of Chiasma’s business as our Chief Executive Officer and Chief Financial Officer and extensive experience in the biopharmaceutical industry qualify him to serve on our Board of Directors.

Basic Compensation

Total Annual Compensation, USD 460,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 215,100
Fiscal Year Total, USD 675,100

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --